Pro-gastrin-releasing peptide as a factor predicting the incidence of brain metastasis in patients with small cell lung carcinoma with limited disease receiving prophylactic cranial irradiation

作者: Kan Yonemori , Minako Sumi , Naoko Fujimoto , Yoshinori Ito , Atsushi Imai

DOI: 10.1002/CNCR.21238

关键词: MetastasisProphylactic cranial irradiationBrain metastasisLung cancerOncologyCancerSurgeryInternal medicineRespiratory diseaseMedicineConventional PCIProgressive diseaseCancer research

摘要: BACKGROUND Prophylactic cranial irradiation (PCI) reduces the incidence of brain metastasis with an effect on overall survival in patients small cell lung carcinoma (SCLC). In spite multidisciplinary intensive treatment approaches, many still experience metastasis. The authors retrospectively analyzed characteristics first failure event due to (FBM) treated PCI. METHODS Between January 1990 and April 2004, 71 limited disease SCLC were PCI after completing systemic at National Cancer Center Hospital (Tokyo, Japan). Univariate multivariate analyses used identify factors related FBM survival. RESULTS The (OBM) 16.9 % (12 71) 26.8% (19 71), respectively. Median time progressive median 8.4 months 21.6 months, Elevation pro-gastrin–releasing peptide (Pro GRP) level before was found be a significant predictive prognostic factor for FBM, OBM, analysis (P = 0.007, P 0.025, 0.009, respectively). CONCLUSIONS An elevated Pro GRP significantly survival, should considered is performed. 2005. © 2005 American Society.

参考文章(27)
Steven T. Rosen, Robert W. Makuch, Allen S. Lichter, Daniel C. Ihde, Mary J. Matthews, John D. Minna, Eli Glatstein, Paul A. Bunn, Role of prophylactic cranial irradiation in prevention of central nervous system metastases in small cell lung cancer The American Journal of Medicine. ,vol. 74, pp. 615- 624 ,(1983) , 10.1016/0002-9343(83)91019-7
W. Whitson, R. Komaki, J. D. Cox, Risk of brain metastasis from small cell carcinoma of the lung related to length of survival and prophylactic irradiation. Cancer treatment reports. ,vol. 65, pp. 811- 814 ,(1981)
K S Albain, J J Crowley, M LeBlanc, R B Livingston, Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base. Journal of Clinical Oncology. ,vol. 8, pp. 1563- 1574 ,(1990) , 10.1200/JCO.1990.8.9.1563
R Arriagada, A Kramar, T Le Chevalier, H De Cremoux, Competing events determining relapse-free survival in limited small-cell lung carcinoma. The French Cancer Centers' Lung Group. Journal of Clinical Oncology. ,vol. 10, pp. 447- 451 ,(1992) , 10.1200/JCO.1992.10.3.447
N Saijo, T Shinkai, T Kasai, Y Ohe, T Tamura, N Yamamoto, T Okusaka, K Eguchi, T Kurata, Serum levels of pro-gastrin-releasing peptide for follow-up of patients with small cell lung cancer. Clinical Cancer Research. ,vol. 3, pp. 123- 127 ,(1997)
M Takada, Y Kusunoki, N Masuda, K Matui, T Yana, S Ushijima, K Iida, K Tamura, T Komiya, I Kawase, N Kikui, H Morino, M Fukuoka, Pro-gastrin-releasing peptide (31-98) as a tumour marker of small-cell lung cancer: comparative evaluation with neuron-specific enolase. British Journal of Cancer. ,vol. 73, pp. 1227- 1232 ,(1996) , 10.1038/BJC.1996.235
Ken Yamaguchi, Katsumi Aoyagi, Ken-ichi Urakami, Toyoharu Fukutani, Noboru Maki, Shigehiro Yamamoto, Kotomi Otsubo, Yoshio Miyake, Tetsuro Kodama, Enzyme-linked Immunosorbent Assay of Pro-gastrin-releasing Peptide for Small Cell Lung Cancer Patients in Comparison with Neuron-specific Enolase Measurement Japanese Journal of Cancer Research. ,vol. 86, pp. 698- 705 ,(1995) , 10.1111/J.1349-7006.1995.TB02455.X
Bruce Borgelt, Richard Gelber, Simon Kramer, Luther W. Brady, Chu H. Chang, Lawrence W. Davis, Carlos A. Perez, Frank R. Hendrickson, The palliation of brain metastases: Final results of the first two studies by the radiation therapy oncology group International Journal of Radiation Oncology Biology Physics. ,vol. 6, pp. 1- 9 ,(1980) , 10.1016/0360-3016(80)90195-9